Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials.
about
Tiotropium versus ipratropium bromide for chronic obstructive pulmonary diseaseLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: an overview and network meta-analysisTiotropium versus ipratropium bromide for chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary diseaseLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisCombined corticosteroid and long-acting beta 2 -agonist in one inhaler versus placebo for chronic obstructive pulmonary diseaseOverview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary diseaseComparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysisPositioning new pharmacotherapies for COPDTen years of tiotropium: clinical impact and patient perspectivesOnce-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacyLong-acting muscarinic receptor antagonists for the treatment of chronic airway diseasesClinical potential of aclidinium bromide in chronic obstructive pulmonary diseaseDrugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysisTiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.Cardiac safety of tiotropium in patients with COPD: a combined analysis of Holter-ECG data from four randomised clinical trials.Evidence synthesis for count distributions based on heterogeneous and incomplete aggregated data.Value and usability of unpublished data sources for systematic reviews and network meta-analyses.Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPDCardiovascular safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort studyImpact of Nonadherence to Inhaled Corticosteroid/LABA Therapy on COPD Exacerbation Rates and Healthcare Costs in a Commercially Insured US Population.Study protocol for a randomized, controlled trial comparing the efficacy of two educational interventions to improve inhalation techniques in patients with chronic obstructive pulmonary disease (COPD): TIEPOC Study.Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary diseaseRisk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study.Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial.Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis.Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis.Personalized pulmonary rehabilitation and occupational therapy based on cardiopulmonary exercise testing for patients with advanced chronic obstructive pulmonary disease.Anti-inflammatory effects of potato extract on a rat model of cigarette smoke-induced chronic obstructive pulmonary disease.Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial.Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular riskSafety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trialPOPE study: rationale and methodology of a study to phenotype patients with COPD in Central and Eastern Europe.The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationaleTiotropium Respimat(®) vs. HandiHaler(®): real-life usage and TIOSPIR trial generalizability.Efficacy and safety of eco-friendly inhalers: focus on combination ipratropium bromide and albuterol in chronic obstructive pulmonary disease.Pharmacotherapies for COPD.Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb studyProfile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD
P2860
Q24187073-CAE34EC5-28C8-4B2F-98D0-2F577A8B4C22Q24197853-737D0A0C-4779-41B7-AAF1-6D55636BDBFCQ24197946-7F4F002A-2C2D-4274-B805-82AAA11BB5B5Q24198068-EB05D744-BAC7-4862-8EF6-9BE756DE9DB4Q24199130-2449B8F2-8B3B-4B5C-ADB1-6E590485548CQ24202279-00A11A29-C654-424F-836F-150A9ECC00E5Q24202510-4FC5D8AA-21D3-435B-B3CB-B5EC7C343CE3Q26741051-70BB96BA-44CC-413A-8FB5-91B60697D9BFQ26778794-02F9D19A-BA07-49EC-85C1-B26BB0657202Q26798659-66B2589E-93D3-42C0-A09D-0F24F0012067Q26823682-EE5B719E-C810-452C-A24C-746BF8C936C9Q27010444-91271C63-393E-4A0A-9776-C00D62AC620BQ27022636-619DFCF4-09CB-451B-A140-D8C286C4A102Q27023223-A0947146-C8C5-449E-85D7-7DACD2BB2D4AQ28258219-44516C31-ECA9-4457-9107-E94A6BC3392EQ30620671-2F759A03-1840-4B96-A20B-94FF8FE752C6Q30877371-DDB6F9F9-4D14-46E7-860F-AF983AB1F45BQ30949429-E8F8BD9F-2C7E-4FF5-A24F-A967E9101537Q31133808-C17A47C5-132F-4CC5-8BA5-0E7F2C026057Q33558856-E98903BF-292C-4286-98CD-C9423588B9FEQ33590384-79DDD5F9-11EC-412A-8D87-46F578D7DE1AQ33795984-BC50F4AB-191C-47BA-90CC-D5BF221EE3B0Q33837011-03CDCBC9-B39B-433F-86C9-61EC581C7251Q34677811-E4CDE776-C57C-43D1-B100-A3D9D710014DQ35675649-263EC68C-648F-4BE2-BC22-BA20B05E9DE7Q35762406-DD07F77E-2975-47CD-AC7C-406BDA84B444Q35778149-14E89538-5199-4C55-8166-7F4099932090Q35838660-C86739B8-77A1-4AC5-B596-6A510DDA9B29Q36037006-4D5C93B0-CD8B-44CC-9433-DC710D39C927Q36206448-EB21B253-6A38-48D9-8676-9E18DDB85EA6Q36251424-3705F5F6-FDDD-4CBD-9EC1-5969EB9D56A3Q36412770-10CE3B3C-4EC6-4CBC-A450-7F5B992A31DEQ36456873-5B1DDF76-5160-48E9-A78B-1603607513FBQ36733544-C1EDE57C-1723-40A7-AC0C-F86697ABB280Q36752114-C8859751-BE01-45A6-A230-DE243219AE3FQ36802125-48763DCE-B992-4459-9EC7-D71C1CEC5A18Q36813641-66512F3E-5C13-405A-841B-D020A4FFE4D7Q36843717-42520A06-CFE0-4DD5-90AF-0C822558C2DBQ37209291-57EC4903-9A67-407C-B740-47127A0907E9Q37614090-EA11696C-58F7-474C-A453-D8BD9773E821
P2860
Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Comparative safety of inhaled ...... randomised controlled trials.
@ast
Comparative safety of inhaled ...... randomised controlled trials.
@en
Comparative safety of inhaled ...... randomised controlled trials.
@nl
type
label
Comparative safety of inhaled ...... randomised controlled trials.
@ast
Comparative safety of inhaled ...... randomised controlled trials.
@en
Comparative safety of inhaled ...... randomised controlled trials.
@nl
prefLabel
Comparative safety of inhaled ...... randomised controlled trials.
@ast
Comparative safety of inhaled ...... randomised controlled trials.
@en
Comparative safety of inhaled ...... randomised controlled trials.
@nl
P2093
P50
P921
P1433
P1476
Comparative safety of inhaled ...... randomised controlled trials.
@en
P2093
Wen-Yi Shau
Yaa-Hui Dong
Yun-Chun Wu
P356
10.1136/THORAXJNL-2012-201926
P407
P577
2012-10-06T00:00:00Z